Detalhe da pesquisa
1.
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.
N Engl J Med
; 389(6): 514-526, 2023 Aug 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37366315
2.
Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH.
N Engl J Med
; 389(11): 998-1008, 2023 Sep 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-37356033
3.
Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.
Lancet
; 402(10403): 720-730, 2023 08 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-37364590
4.
Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study.
Lancet
; 402(10400): 472-483, 2023 08 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37369232
5.
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
Lancet
; 402(10402): 613-626, 2023 08 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-37385275
6.
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
N Engl J Med
; 385(6): 503-515, 2021 08 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34170647
7.
Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 Study.
Clin Gastroenterol Hepatol
; 2024 Mar 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38447814
8.
Cardiovascular efficacy and safety of antidiabetic agents: A network meta-analysis of randomized controlled trials.
Diabetes Obes Metab
; 25(12): 3560-3577, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37649320
9.
Tolerability, safety and pharmacodynamics of oral, small-molecule glucagon-like peptide-1 receptor agonist danuglipron for type 2 diabetes: A 12-week, randomized, placebo-controlled, Phase 2 study comparing different dose-escalation schemes.
Diabetes Obes Metab
; 25(10): 2805-2814, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37311722
10.
A 96-week, double-blind, randomized controlled trial comparing bexagliflozin to glimepiride as an adjunct to metformin for the treatment of type 2 diabetes in adults.
Diabetes Obes Metab
; 25(1): 293-301, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36178197
11.
iGlarLixi versus basal plus Rapid-Acting insulin in adults with type 2 diabetes advancing from basal insulin therapy: The SoliSimplify Real-World study.
Diabetes Obes Metab
; 25(1): 68-77, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36123617
12.
A microbiome-targeting fibre-enriched nutritional formula is well tolerated and improves quality of life and haemoglobin A1c in type 2 diabetes: A double-blind, randomized, placebo-controlled trial.
Diabetes Obes Metab
; 25(5): 1203-1212, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36594522
13.
Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes: The SURPASS-6 Randomized Clinical Trial.
JAMA
; 330(17): 1631-1640, 2023 11 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37786396
14.
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.
Lancet
; 398(10300): 583-598, 2021 08 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-34370970
15.
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.
Lancet
; 398(10295): 143-155, 2021 07 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34186022
16.
Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis.
Gastroenterology
; 160(1): 219-231.e1, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32781086
17.
Long-term effects of dapagliflozin plus saxagliptin versus glimepiride on a background of metformin in patients with type 2 diabetes: Results of a 104-week extension to a 52-week randomized, phase 3 study and liver fat MRI substudy.
Diabetes Obes Metab
; 24(1): 61-71, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34514692
18.
Glycaemic efficacy of an expanded dose range of dulaglutide according to baseline glycated haemoglobin (HbA1c) subgroup: Post hoc analysis of AWARD-11.
Diabetes Obes Metab
; 23(12): 2819-2824, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34463420
19.
Effect of dulaglutide 3.0 and 4.5 mg on weight in patients with type 2 diabetes: Exploratory analyses of AWARD-11.
Diabetes Obes Metab
; 23(10): 2242-2250, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34189841
20.
Efficacy and safety of dulaglutide 3.0 and 4.5 mg in patients aged younger than 65 and 65 years or older: Post hoc analysis of the AWARD-11 trial.
Diabetes Obes Metab
; 23(10): 2279-2288, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34159708